

RECEIVED
CENTRAL FAX CENTER

SEP 06 2006

Atty. Dkt. No. 041673-1001

CORRECTED PAGE RESPONSIVE TO NOTICE OF NON-COMPLIANT AMENDMENT

Amendments to the Claims:

Claims 1-69 and 73-76 were previously cancelled. Claims 70, 90 and 92 are currently being amended. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-69 (Cancelled)

70. (Currently Amended) A method for increasing the efficiency of transduction of a gene into cardiac muscle to treat ~~cardiac disease~~ heart failure in a patient, wherein the gene comprises a mutated form of a phospholamban (PLB) gene, and the method comprises the step of administering a viral vector comprising the mutated PLB gene to the heart while the patient is in a state of hypothermia.

71. (Previously Presented) The method of claim 70, wherein the gene is administered in a viral gene expression vector.

72. (Previously Presented) The method of claim 70, wherein the viral gene expression vector further comprises a promoter suitable for use in cardiac muscle.

73. - 76. (Cancelled)

77. (Previously Presented) The method of claim 70, wherein the viral gene expression vector is an adeno-associated viral vector (AAV).

78. (Previously Presented) The method of claim 70, further comprising co-administering a sarcoplasmic reticulum CA2+ ATPase (SERCA-2) gene with the PLB gene to the cardiac muscle.

79. (Previously Presented) The method of claim 70, wherein the PLB gene is a dominant negative PLB gene.